HPAPI for Drug Development and Delivery

“Highly potent APIs (HPAPIs) have grown in popularity over the last decade and are increasingly enabling innovators to develop targeted, low-dose therapies for patients who need them the most. These compounds, known for their significant biological effects at very low concentrations, offer immense potential for treating various diseases, including cancer, autoimmune disorders, diabetes and more conditions. However, the journey from molecule to market for an HPAPI is complex, requiring specialized expertise and infrastructure. Therefore, it is crucial to explore how the industry can navigate these challenges to effectively scale up the development and manufacture of these vital therapeutics.”

Veranova’s Vice President and General Manager, Lucas Sauer-Jones, spoke with International Pharmaceutical Industry Journal to discuss the role of contract development and manufacturing organizations (CDMOs) in addressing HPAPI production challenges, emphasizing the importance of advanced analytical techniques, regulatory compliance, and safety measures.

Read the full article in IPI , Volume 16 Issue 4, pages 29-31